KBC Group NV Boosts Position in RxSight, Inc. (NASDAQ:RXST)

KBC Group NV increased its holdings in RxSight, Inc. (NASDAQ:RXST) by 63.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,232 shares of the company’s stock after acquiring an additional 479 shares during the quarter. KBC Group NV’s holdings in RxSight were worth $61,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. CWM LLC lifted its position in shares of RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC raised its stake in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Quest Partners LLC purchased a new stake in RxSight in the second quarter worth about $41,000. Amalgamated Bank boosted its position in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of RxSight during the 2nd quarter worth approximately $156,000. Institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

RXST has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus decreased their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Oppenheimer dropped their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Finally, Jefferies Financial Group initiated coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $61.63.

Insider Activity at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,225,096.82. This trade represents a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jesse Anderson Corley acquired 11,111 shares of RxSight stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $45.37 per share, with a total value of $504,106.07. Following the completion of the acquisition, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 52,720 shares of company stock valued at $2,603,950 over the last 90 days. Corporate insiders own 9.36% of the company’s stock.

RxSight Stock Performance

Shares of RxSight stock opened at $44.83 on Friday. The company has a 50-day simple moving average of $49.39 and a two-hundred day simple moving average of $52.73. The stock has a market capitalization of $1.81 billion, a PE ratio of -54.01 and a beta of 1.19. RxSight, Inc. has a 52-week low of $28.54 and a 52-week high of $66.54.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.